Highlight
- Finerenone slows estimated glomerular filtration rate (eGFR) decline in hypertensive non-diabetic chronic kidney disease (CKD).
- It significantly reduces the composite kidney-cardiovascular outcome including kidney failure and cardiovascular events.
- The benefits occur regardless of baseline systolic blood pressure levels.
- Finerenone’s safety is acceptable, with hyperkalaemia being the primary adverse event, rarely leading to treatment discontinuation.
